#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean
A little more than a year after Yescarta was approved as the first CAR-T for third-line therapy in large B-cell lymphoma, researchers are still trying to determine what the median overall survival rate for patients is. It hasn’t been reached.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.